| Literature DB >> 28518018 |
Cheryl P Andam, Colin J Worby, Ryan Gierke, Lesley McGee, Tamara Pilishvili, William P Hanage.
Abstract
Introduction of 13-valent pneumococcal conjugate vaccine in the United States was not associated with a significant change in prevalence of penicillin resistance in nonvaccine type serotypes because of the variable success of highly resistant serotypes. Differences in regional serotype distribution and serotype-specific resistance contributed to geographic heterogeneity of penicillin resistance.Entities:
Keywords: 13-valent pneumococcal conjugate vaccine; PCV13; Streptococcus pneumoniae; United States; antibiotic resistance; antimicrobial resistance; bacteria; bacterial infection; geographic variation; nonvaccine type; penicillin; pneumococcus; serotype; temporal variation; vaccines
Mesh:
Substances:
Year: 2017 PMID: 28518018 PMCID: PMC5443431 DOI: 10.3201/eid2306.161331
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Comparison of proportion of nonvaccine type serotypes with penicillin resistance, by serotype, United States, 2009 and 2012. Based on Active Bacterial Core surveillance system data from 10 US states. The dashed diagonal line represents no change.
Figure 2Crude versus standardized proportions of nonvaccine type serotypes with penicillin nonsusceptibility, by state, United States, 2009 and 2012, based on Active Bacterial Core surveillance system data from 10 US states. Std1 denotes standardization for geographic heterogeneity in serotype distribution. Std2 denotes standardization for serotype-specific differences in resistance. Regression slopes with 95% CIs are indicated in the upper left corner of each panel. Larger circles represent states with a greater number of penicillin-resistant samples. Dashed lines represent the inverse-variance weighted (red) and unweighted (gray) regression slopes. PNSP, penicillin-nonsusceptible pneumococcus.